Efficacy, Immunogenicity, and Safety Study of Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection
Principal Investigator
Theodore SteinerOverview
Body Locations and Systems
Clostridium Difficile InfectionsHealth Conditions
Clostridium Difficile InfectionClinicalTrials.gov#
NCT01887912Status
Closed for RecruitmentStudy Start/End
Sep 30, 2016 to Dec 31, 2017Locations
Diamond Health Care Centre, Vancouver General Hospital
Name/Title
Neila Tong, Research CoordinatorPhone
604-875-4111 ext.62178Email Address
neila.tong@vch.caPurpose of Study
The aim of this study is to evaluate the efficacy of the candidate Clostridium difficile (C. difficile) vaccine to prevent primary symptomatic C. difficile infection (CDI) in subjects a risk for CDI where there is a substantial unmet medical need.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.